Core Insights - Alvotech and Advanz Pharma have entered into a supply and commercialization agreement for AVT10, a biosimilar candidate to Cimzia® (certolizumab pegol) [1][3] - This agreement is significant as AVT10 is the only biosimilar candidate referencing Cimzia® under development globally, targeting chronic rheumatic diseases [2][3] - The partnership aims to expand access to high-quality biologics for patients in Europe, with plans to launch their first biosimilars in Q4 2025 [4] Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, with a pipeline that includes eight disclosed biosimilar candidates for various diseases [6] - Advanz Pharma specializes in specialty, hospital, and rare disease medicines, with a commercial presence in over 90 countries and a diverse product portfolio [7][8] Market Context - Cimzia® generated worldwide sales of US$2.3 billion in 2024, indicating a substantial market opportunity for Alvotech's biosimilar candidate [3] - The strategic partnership between Alvotech and Advanz Pharma is expected to enhance their biosimilars pipeline and strengthen their market position in Europe [3][4]